Search details
1.
CD74 is associated with inflamed tumor immune microenvironment and predicts responsiveness to PD-1/CTLA-4 bispecific antibody in patients with solid tumors.
Cancer Immunol Immunother
; 73(2): 36, 2024 Jan 27.
Article
in English
| MEDLINE | ID: mdl-38280003
2.
Safety and antitumour activity of cadonilimab, an anti-PD-1/CTLA-4 bispecific antibody, for patients with advanced solid tumours (COMPASSION-03): a multicentre, open-label, phase 1b/2 trial.
Lancet Oncol
; 24(10): 1134-1146, 2023 Oct.
Article
in English
| MEDLINE | ID: mdl-37797632
3.
Penpulimab, an anti-PD1 IgG1 antibody in the treatment of advanced or metastatic upper gastrointestinal cancers.
Cancer Immunol Immunother
; 71(10): 2371-2379, 2022 Oct.
Article
in English
| MEDLINE | ID: mdl-35165764
4.
Phase 1a dose escalation study of ivonescimab (AK112/SMT112), an anti-PD-1/VEGF-A bispecific antibody, in patients with advanced solid tumors.
J Immunother Cancer
; 12(4)2024 Apr 19.
Article
in English
| MEDLINE | ID: mdl-38642937
5.
Cadonilimab Combined with Chemotherapy with or without Bevacizumab as First-Line Treatment in Recurrent or Metastatic Cervical Cancer (COMPASSION-13): A Phase 2 Study.
Clin Cancer Res
; 30(8): 1501-1508, 2024 Apr 15.
Article
in English
| MEDLINE | ID: mdl-38372727
6.
A Phase 1b Study of Ivonescimab, a Programmed Cell Death Protein-1 and Vascular Endothelial Growth Factor Bispecific Antibody, as First- or Second-Line Therapy for Advanced or Metastatic Immunotherapy-Naive NSCLC.
J Thorac Oncol
; 19(3): 465-475, 2024 Mar.
Article
in English
| MEDLINE | ID: mdl-37879536
7.
Cadonilimab with chemotherapy in HER2-negative gastric or gastroesophageal junction adenocarcinoma: the phase 1b/2 COMPASSION-04 trial.
Nat Med
; 2024 May 22.
Article
in English
| MEDLINE | ID: mdl-38778212
8.
Cadonilimab, a tetravalent PD-1/CTLA-4 bispecific antibody with trans-binding and enhanced target binding avidity.
MAbs
; 15(1): 2180794, 2023.
Article
in English
| MEDLINE | ID: mdl-36872527
9.
A multicenter, open-label phase Ib/II study of cadonilimab (anti PD-1 and CTLA-4 bispecific antibody) monotherapy in previously treated advanced non-small-cell lung cancer (AK104-202 study).
Lung Cancer
; 184: 107355, 2023 10.
Article
in English
| MEDLINE | ID: mdl-37677918
10.
A phase 1a/1b first-in-human study (COMPASSION-01) evaluating cadonilimab in patients with advanced solid tumors.
Cell Rep Med
; 4(11): 101242, 2023 11 21.
Article
in English
| MEDLINE | ID: mdl-37852261
11.
AK112, a novel PD-1/VEGF bispecific antibody, in combination with chemotherapy in patients with advanced non-small cell lung cancer (NSCLC): an open-label, multicenter, phase II trial.
EClinicalMedicine
; 62: 102106, 2023 Aug.
Article
in English
| MEDLINE | ID: mdl-37593227
12.
The efficacy and safety of cadonilimab combined with lenvatinib for first-line treatment of advanced hepatocellular carcinoma (COMPASSION-08): a phase Ib/II single-arm clinical trial.
Front Immunol
; 14: 1238667, 2023.
Article
in English
| MEDLINE | ID: mdl-37942328
13.
Ligufalimab, a novel anti-CD47 antibody with no hemagglutination demonstrates both monotherapy and combo antitumor activity.
J Immunother Cancer
; 10(11)2022 11.
Article
in English
| MEDLINE | ID: mdl-36450383
Results
1 -
13
de 13
1
Next >
>>